Bristol-Myers (BMY) PT Raised to $70 at Credit Suisse on 'Stunningly Quick' Opdivo Approval
Get Alerts BMY Hot Sheet
Rating Summary:
6 Buy, 26 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 10
Join SI Premium – FREE
Credit Suisse analyst V. Divan reiterated a Outperform rating and boosted its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $70.00 (from $68.00) following the FDA's "stunningly quick approval of Opdivo in previously-treated squamous non-small cell lung cancer (NSCLC) is a significant upside surprise for BMY, both in terms of timing and breadth."
Divan said the quick approval provides upside to sales/EPS in 2015-2017. The firm raised estimates accordingly.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $65.67 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK185 at Telsey, 'encouraged by the topline momentum'
- Canaccord Genuity Downgrades Pivotree (PVT:CN) to Hold
- Morgan Stanley Downgrades Sanbio Co Ltd. (4592:JP) (SNBIF) to Equalweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT Change, FDARelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!